Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea

INTRODUCTION: The objective of this study was to evaluate the cost-effectiveness of initiating treatment with tofacitinib and subsequently incorporating it into a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) treatment sequence and to compare the cost-effectiveness of this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, So-Young, Shim, Yoon-Bo, Lee, Min-Young, Koo, Bon-San, Kim, Jae-Hoon, Jeon, Ja-Young, Yoo, Hyun-Jeong, Kim, Young-Joo, Shin, Ju-Young, Park, Mi-Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991041/
https://www.ncbi.nlm.nih.gov/pubmed/33496958
http://dx.doi.org/10.1007/s40744-021-00278-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991041/
https://www.ncbi.nlm.nih.gov/pubmed/33496958
http://dx.doi.org/10.1007/s40744-021-00278-z

Ejemplares similares